Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients

被引：13

作者：

Bellmunt, Joaquim ^{[1
]}

Fishman, Mayer ^{[2
]}

Eisen, Timothy ^{[3
]}

Quinn, David ^{[4
]}

机构：

[1] Univ Hosp Mar IMIM, RTICC, Barcelona 08003, Spain

[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[3] Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 0QQ, England

[4] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2010年 / 10卷 / 06期

关键词：

elderly; multiple lines of therapy; patient adherence; quality of life; renal cell carcinoma; sorafenib; systemic therapy; watch and wait; KIDNEY CANCER; KINASE INHIBITORS; INTERFERON-ALPHA; OLDER PATIENTS; EFFICACY; THERAPY; SAFETY; HYPERTENSION; TEMSIROLIMUS; SUNITINIB;

D O I：

10.1586/ERA.10.68

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The incidence of renal cell carcinoma is increasing globally. Targeted agents offer treatment options that were not available less than a decade ago. However, it is important to carefully select therapy for each individual patient, weighing both the drug efficacy and tolerability profile and patient-related factors, such as adherence, age and comorbidities. Based on our clinical experience in treating patients with renal cell carcinoma, this article offers our opinions on factors that characterize patients for whom sorafenib may serve as a viable first-line therapeutic option.

引用

页码：825 / 835

页数：11

共 75 条

[51] Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301 [J].

Miller, Antonius A. ;

Murry, Daryl J. ;

Owzar, Kouros ;

Hollis, Donna R. ;

Kennedy, Erin B. ;

Abou-Alfa, Ghassan ;

Desai, Apurva ;

Hwang, Jimmy ;

Villalona-Calero, Miguel A. ;

Dees, E. Claire ;

Lewis, Lionel D. ;

Fakih, Marwan G. ;

Edelman, Martin J. ;

Millard, Fred ;

Frank, Richard C. ;

Hohl, Raymond J. ;

Ratain, Mark J. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) :1800-1805

[52] Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial [J].

Motzer, Robert J. ;

Escudier, Bernard ;

Oudard, Stephane ;

Hutson, Thomas E. ;

Porta, Camillo ;

Bracarda, Sergio ;

Gruenwald, Viktor ;

Thompson, John A. ;

Figlin, Robert A. ;

Hollaender, Norbert ;

Urbanowitz, Gladys ;

Berg, William J. ;

Kay, Andrea ;

Lebwohl, David ;

Ravaud, Alain .

LANCET, 2008, 372 (9637) :449-456

[53]

National Comprehensive Cancer Network (NCCN), NCCN PRACT GUID ONC

[54] Safety and Efficacy of Sorafenib Therapy in Patients With Metastatic Kidney Cancer With Impaired Renal Function [J].

Parsa, Venkata ;

Heilbrun, Lance ;

Smith, Daryn ;

Sethi, Aastha ;

Vaishampayan, Ulka .

CLINICAL GENITOURINARY CANCER, 2009, 7 (02) :E10-E15

[55] Epidemiology of Kidney Cancer [J].

Pascual, D. ;

Borque, A. .

ADVANCES IN UROLOGY, 2008, 2008

[56]

PORTA C, 2008, ANN ONCOL, V19

[57] Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma [J].

Ratain, Mark J. ;

Eisen, Tim ;

Stadler, Walter M. ;

Flaherty, Keith T. ;

Kaye, Stan B. ;

Rosner, Gary L. ;

Gore, Martin ;

Desai, Apurva A. ;

Patnaik, Amita ;

Xiong, Henry Q. ;

Rowinsky, Lric ;

Abbruzzese, James L. ;

Xia, Chenghua ;

Simantov, Ronit ;

Schwartz, Brian ;

O'Dwyer, Peter J. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) :2505-2512

[58] Renal cell carcinoma [J].

Rini, Brian I. ;

Campbell, Steven C. ;

Escudier, Bernard .

LANCET, 2009, 373 (9669) :1119-1132

[59] Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor [J].

Robinson, Emily S. ;

Matulonis, Ursula A. ;

Ivy, Percy ;

Berlin, Suzanne T. ;

Tyburski, Karin ;

Penson, Richard T. ;

Humphreys, Benjamin D. .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (03) :477-483

[60] Patient Adherence and Persistence With Oral Anticancer Treatment [J].

Ruddy, Kathryn ;

Mayer, Erica ;

Partridge, Ann .

CA-A CANCER JOURNAL FOR CLINICIANS, 2009, 59 (01) :56-66

← 1 2 3 4 5 6 7 8 →